A detailed history of Commonwealth Equity Services, LLC transactions in Ginkgo Bioworks Holdings, Inc. stock. As of the latest transaction made, Commonwealth Equity Services, LLC holds 305,467 shares of DNA stock, worth $2.49 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
305,467
Previous 381,688 19.97%
Holding current value
$2.49 Million
Previous $443,000 76.98%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 31, 2024

SELL
$0.28 - $1.16 $21,341 - $88,416
-76,221 Reduced 19.97%
305,467 $102,000
Q1 2024

Apr 29, 2024

BUY
$1.06 - $1.67 $4,015 - $6,325
3,788 Added 1.0%
381,688 $443,000
Q4 2023

Feb 06, 2024

BUY
$1.26 - $1.79 $11,137 - $15,821
8,839 Added 2.39%
377,900 $639,000
Q3 2023

Oct 23, 2023

BUY
$1.61 - $2.54 $204,347 - $322,386
126,924 Added 52.42%
369,061 $668,000
Q2 2023

Aug 10, 2023

BUY
$1.14 - $1.95 $61,082 - $104,482
53,581 Added 28.42%
242,137 $450,000
Q1 2023

May 11, 2023

BUY
$1.2 - $2.19 $27,592 - $50,356
22,994 Added 13.89%
188,556 $250,000
Q4 2022

Feb 07, 2023

SELL
$1.63 - $3.52 $18,583 - $40,131
-11,401 Reduced 6.44%
165,562 $279,000
Q3 2022

Nov 14, 2022

BUY
$0.73 - $3.74 $27,229 - $139,502
37,300 Added 26.71%
176,963 $552,000
Q2 2022

Jul 19, 2022

BUY
$2.2 - $4.2 $96,771 - $184,745
43,987 Added 45.97%
139,663 $332,000
Q1 2022

May 04, 2022

BUY
$2.83 - $8.69 $73,039 - $224,280
25,809 Added 36.94%
95,676 $385,000
Q4 2021

Jan 31, 2022

SELL
$8.31 - $14.92 $58,485 - $105,006
-7,038 Reduced 9.15%
69,867 $580,000
Q3 2021

Oct 29, 2021

BUY
$9.15 - $13.28 $703,680 - $1.02 Million
76,905 New
76,905 $891,000

Others Institutions Holding DNA

About Ginkgo Bioworks Holdings, Inc.


  • Ticker DNA
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 1,287,779,968
  • Market Cap $10.5B
  • Description
  • Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agric...
More about DNA
Track This Portfolio

Track Commonwealth Equity Services, LLC Portfolio

Follow Commonwealth Equity Services, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Commonwealth Equity Services, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Commonwealth Equity Services, LLC with notifications on news.